Pfizer discontinues hemophilia treatment Beqvez, emptying its gene therapy portfolio
By Angus Liu,
Fierce Pharma
| 02. 21. 2025
Pfizer is pulling further away from the gene therapy field with its decision to discontinue hemophilia product Beqvez.
The New York pharma is ending global development and commercialization of Beqvez less than a year after an FDA approval for the gene therapy to treat hemophilia B. The one-time treatment carried a list price of $3.5 million per person.
Several reasons led to the discontinuation, including limited interest from patients and doctors toward hemophilia gene therapies to date, a Pfizer spokesperson told Fierce Pharma in a statement.
No patients seem to have received commercial Beqvez since its FDA nod in April 2024. The Pfizer spokesperson said the company will communicate the news to patients and providers that are in the treatment qualification process, adding that the company remains committed to supporting those who received the med in any clinical trial.
Following Beqvez’s exit from the market, Pfizer has no commercial or clinical-stage gene therapies left in the works, according to its website. The spokesperson confirmed that the company doesn’t have any active gene therapy programs at the moment.
Step by step...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Jan Grue, The Guardian | 10.27.2026
For a very long time, I dreamed of being cured. I was born in 1981. I learned to walk early enough, but I stumbled and fell more easily than other children. My parents began to worry that something was wrong...
By Gary Sernovitz, Bloomberg | 10.21.2026
Three years ago, at the age of 50, I found out I have dangerous genes. So in June, I went to Cambridge, Massachusetts, to see how they could be fixed. Among my 6 billion base pairs of DNA are two...
By Carl Zimmer, The New York Times | 10.20.2026
For the first time, scientists say they have used viruses designed by artificial intelligence to treat a human patient.
Researchers announced on Tuesday that they had administered the virus, known as a phage, to a patient suffering from a deadly...